NASDAQ:PETX Aratana Therapeutics (PETX) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free petx Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$4.92▼$4.9250-Day Range$4.92▼$4.9252-Week Range$3.30▼$7.16VolumeN/AAverage Volume1.03 million shsMarket Capitalization$241.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aratana Therapeutics alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Aratana Therapeutics Stock (NASDAQ:PETX)Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. It is also developing NOCITA, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-016, allogeneic adipose-derived stem cells for dogs; and AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications. In addition, the company develops AT-008, a therapeutic candidate for treating canine lymphoma in dogs; and other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; Pacira Pharmaceuticals, Inc. to develop and commercialization of licensed animal health products for NOCITA; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> PETX Stock News HeadlinesSeptember 9, 2023 | finance.yahoo.comAratana's Drug Pipeline Suggests Revenue Growth Could Continue For YearsAugust 20, 2022 | investing.comPETX_old Historical DataApril 26, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 19, 2022 | thestreet.comBiotech Premarket Movers: Editas, Amphastar, Aratana, PaciraJanuary 14, 2022 | thestreet.com5 Stocks Under $10 to Trade for Big BreakoutsOctober 26, 2021 | finance.yahoo.comAratana (PETX) Tops Q3 Earnings and Revenue EstimatesSee More Headlines Receive PETX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aratana Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2018Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PETX CUSIPN/A CIK1509190 Webwww.aratana.com Phone913-353-1000FaxN/AEmployees83Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,720,000.00 Net Margins-33.47% Pretax MarginN/A Return on Equity-12.99% Return on Assets-10.82% Debt Debt-to-Equity RatioN/A Current Ratio6.66 Quick Ratio5.32 Sales & Book Value Annual Sales$35.41 million Price / Sales6.81 Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book2.38Miscellaneous Outstanding Shares49,000,000Free FloatN/AMarket Cap$241.08 million OptionableOptionable Beta1.40 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Craig A. Tooman (Age 53)Pres, CEO & Board Director Ms. Rhonda L. Hellums (Age 47)CFO & Treasurer Mr. John C. Ayres J.D. (Age 40)VP of Corp. Devel. and Admin., Gen. Counsel & Sec. Mr. Brent A. Standridge (Age 61)Consultant Ms. Rachel ReiffHead of Corp. CommunicationsKey CompetitorsVerastemNASDAQ:VSTM23andMeNASDAQ:ME2seventy bioNASDAQ:TSVTAC ImmuneNASDAQ:ACIUPuma BiotechnologyNASDAQ:PBYIView All Competitors PETX Stock Analysis - Frequently Asked Questions How were Aratana Therapeutics' earnings last quarter? Aratana Therapeutics Inc (NASDAQ:PETX) released its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. The biopharmaceutical company earned $21.56 million during the quarter, compared to analyst estimates of $5.70 million. Aratana Therapeutics had a negative net margin of 33.47% and a negative trailing twelve-month return on equity of 12.99%. What other stocks do shareholders of Aratana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aratana Therapeutics investors own include Celldex Therapeutics (CLDX), Synergy Pharmaceuticals (SGYP), Corcept Therapeutics (CORT), Exelixis (EXEL), Pieris Pharmaceuticals (PIRS), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Ayala Pharmaceuticals (ADXS), Aurinia Pharmaceuticals (AUPH) and Progenics Pharmaceuticals (PGNX). This page (NASDAQ:PETX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJim Cramer’s “The Biggest Drug Ever”Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aratana Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.